p53, c-erb B-2 and nm23 expression have no prognostic significance in primary pulmonary adenocarcinoma

European Journal of Cardio-thoracic Surgery

Volumn 11, Issue 5, 1997, Pages 838-842

  MacKinnon, M ^a   Kerr, K M ^a   King, G ^a   Kennedy, M M ^a   Cockburn, J S ^a   Jeffrey, R R ^a  

^a ABERDEEN ROYAL INFIRMARY   (United Kingdom)

Author keywords

Adenocarcinoma; c erb B 2; Immunohistochemistry; Lung; nm23; p53

Indexed keywords

GENE PRODUCT; ONCOPROTEIN; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; ONCOGENE C ERB; PRIORITY JOURNAL; PROGNOSIS; SUPPRESSOR GENE; TUMOR SUPPRESSOR GENE;

ADENOCARCINOMA; FEMALE; HUMANS; LUNG; LUNG NEOPLASMS; MALE; MIDDLE AGED; MONOMERIC GTP-BINDING PROTEINS; NUCLEOSIDE-DIPHOSPHATE KINASE; PROGNOSIS; RECEPTOR, ERBB-2; TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0030965022     PISSN: 10107940     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1010-7940(97)01162-7     Document Type: Article

References (21)

1. Engel M, Theisinger B, Seib T, Seitz G, Huwer H, Zang KD, Welter C. High levels of nm23-H1 and nm23-H2 mRNA in human squamous cell lung carcinoma are associated with poor differentiation and advanced tumour stages. Int J Cancer 1993;55:375-379.
2. Hall PA, Lane DP. p53 In tumour pathology: can we trust immunohistochemistry? - revisited. J Pathol 1994;172:1-4.
3. Higashiyama M, Doi O, Yokouchi H, Kodama K, Nakamori S, Tateishi R, Kimura N. Immunohistochemical analysis of nm23 gene product/NDP kinase expression in pulmonary adenocarcinoma: lack of prognostic value. Br J Cancer 1992;66:533-536.
4. Hiyoshi H, Matsuno Y, Kato H, Shimosato Y, Hirohashi S. Clinicopathological significance of nuclear accumulation of tumours suppressor gene product in primary lung cancer. Jpn J Cancer Res 1992;83(1):101-106.
5. Hsu S, Raine L, Fanger H. The use of antiavidin antibody and avidin-biotin-peroxidase complex in immunoperoxidase techniques. Am J Clin Pathol 1981;75(6):816-821.
6. Iggo R, Gatter K, Bartek I, Lane D, Harris AL. Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet 1990;355:675-679.
7. Kern JA, Schwartz DA, Nordberg JE, Weiner DB, Greene MJ, Torney L, Robinson RA. p185 Expression in human lung adenocarcinoma predicts shortened survival. Cancer Res 1990;50:5184-5191.
8. Kern JA, Slebos RJC, Top B, Rodenhuis S, Lager D, Robinson RA, Weiner D, Schwartz DA. c-erb B-2 Expression and codon 12 K-ras mutations both predict shortened survival for patients with pulmonary adenocarcinoma. J Clin Invest 1994;93:516-520.
9. Kodera Y, Isobe K, Yamauchi M, Kondoh K, Kimura N, Akiyama S, Itoh K, Nakashima I, Takagi H. Expression nm23-H1 RNA levels in human gastric cancer tissues. Cancer 1994;73:259-265.
10. Levine AJ, Py ME, Chang A, Silver A, Dittmer D, Wu M, Welsh D. The 1993 Walter Hubert lecture: the role of the p53 tumour suppressor gene in tumourigenesis. Br J Cancer 1994;69:409-416.
11. Liotta LA, Steeg PS, Stetler-Stevenson WG. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 1991;64:327-336.
12. McLaren R, Kuzu I, Dunnill M, Harris A, Lane D, Gatter KC. The relationship of p53 immunostaining to survival in carcinoma of the lung. Br J Cancer 1992;66:735-738.
13. Mountain CF. A new international staging for lung cancer. Chest 1989;4:225s-233s.
14. Press MF, Hung G, Godolphin W, Slamon D. Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression. Cancer Res 1994;54:2771-2777.
15. Royds JA, Rees RC, Stephenson TJ. nm23 - A metastasis suppressor gene? J Pathol 1994;173:211-212.
16. Royds JA, Stephenson TJ, Rees RC. nm23 Protein expression in ductal, in situ and invasive human breast carcinoma. J Natl Cancer Inst 1993;85:727-731.
17. Steeg PS, Bevilacqua G, Kopper L, Thorgeirson UP, Talmadge JE, Liotta LA, Sobel ME. Evidence of a novel gene associated with low tumour metastatic potential. J Natl Cancer Inst 1988;80:200-204.
18. Tateishi M, Teruyoshi I, Mitsudomi T, Kaneko S, Sugimachi K. Prognostic value of c-erb B-2 protein expression in human lung adenocarcinoma and squamous cell carcinoma. Eur J Cancer 1991;27:1372-1375.
19. Westra WH, Offerhaus GJA, Goodman SN, Slebos RJC, Polak M, Baas IO, Rodehuis S, Hruban RH. Overexpression of the p53 tumour suppressor gene product in primary lung adenocarcinomas is associated with cigarette smoking. Am J Surg Pathol 1993;17(3):213-220.
20. Wynford-Thomas D. p53 In tumour pathology: can we trust immunocytochemistry? J Pathol 1992;166:329-330.
21. Yu D, Wang S, Dulski KM, Tsai C, Nicholson GL, Hung M. c-erb B-2/neu overexpression enhances metastatic potential of human lung cancer cells by induction of metastasis-associated properties. Cancer Res 1994;54:3260-3266.